chrisvoncsefalvay/vaers-outcomes huggingface dataset:
He received the vaccine, then had a two-hour car ride home. He noticed symptoms after he got out of the car and attempting to stand afterwards, said he could barely stand after the car ride. Also reported tremors in his hands and difficulty holding items. Symptoms worsened and included tremors, double vision, and loss of control of motor functioning in his hands and feet. Symptoms lasted for a few hours, improved by the evening after resting, and were completely gone by the following day. Denied chest pain, numbness, change in vital signs or breathing. Patient has never experienced a reaction to a vaccine in the past. Blood glucose and blood pressure were both stable during this event.
Information has been received from a nurse via a company representative referring to multiple patients of unknown age and gender. The patients concurrent and historical conditions were not reported. The nurse stated that some people had been vaccinated with PNEUMOVAX23 (subcutaneous, dose, lot # and expiration date were not reported) within 5 years on unspecified dates and had been re-administered inappropriately (inappropriate schedule of vaccine administered). On unknown dates the patients reported severe injection site reactions. They reported sensations of heat, erythema, soreness, and swelling. Health department had generally been stating that in time the symptoms would resolve. The final outcome of the events was unknown. Additional information is not expected as we have no consent to contact the physician.
Vaccine admin 8-1-11; presented to office 8-3-11 with red, warm, swollen 3x5cm circumferential area involving (L) deltoid.
Left leg below knee to foot has been numb and tinkling like it is also rep since Thursday 2 days after the vacinne
12 hour after the injection my period started,  and I had strong pain in my lower abdomen.  On 10/13/21 I woke up to s strong pain and swelling  in my right calf.
Headache, extreme fatigue,  congestion, runny nose, cough, body ache, facial numbness, emotional /mental distress
No further AE; temperature excursion involving multiple lot numbers for GARDASIL 9, MMR II, ROTATEQ, and RECOMBIV AX. Many of the vaccines have been administered to patients; This spontaneous report was received from a practice manager who was reporting on patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history, drug reactions or allergies and concomitant therapies provided.  24-SEP-2020, the patient was vaccinated with an improperly stored dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (dose, strength, route of administration, anatomical location were not reported; lot number R021636 was confirmed to be valid, expiration date 12-MAY-2021) for prophylaxis. Administered dose of vaccine was stored in a temperature of 1.1 degrees Celsius for 27 hour and 45 minutes and at temperature of 9 degrees Celsius for 1 hour and 15 minutes. Data logger was involved. There were no previous excursions reported. There were no further adverse events reported.  This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: GARDASIL 9 SYRINGE (DEVICE); commondevicename: HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: R021636; expirationdate: 12-MAY-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other;  followupadditionalinfo :Yes; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability
Large local inflammatory reaction in left arm s/p IPV & VARIVAX in that arm.
No other AE details available at this time; Caller reported temperature excursion; This spontaneous report as received from a registered nurse referring to a 4 years old patient of unknown gender. The patient's medical history, concurrent conditions, previous drug reactions or allergies and concomitant therapies were unknown.  On 07-DEC-2020, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (albumin status recombinant human albumin (rHA)) (strength and route were not reported, lot # T021638 has been verified as valid, expiration date was reported as 21-FEB-2021, but upon internal validation established as 21-DEC-2021) 0.5 ml for prophylaxis.  The administrated measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) experienced product storage error with temperature excursion: minus 13.3 degree Celsius, time frame: 4 hours and 15 minutes. There were no previous temperature excursions. The digital data logger was involved. No other adverse event details available at the reporting time.
Numbness from middle of chin up to above ear. Some tingling. No problem with first two shots. This was his third Hep B. Left side.
Pt was observed to drop her  phone on the floor. When it was picked up & RN attempted to hand it to her, she appeared to be sleeping.  She did wake after physical stimulus but was lethargic, confused & stated she "felt dizzy"
This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 19Mar2021 at 12:30 (at the age of 39-years-old), as a single dose for COVID-19 immunisation. Medical history included arthritis in the right shoulder and seasonal and pet dander allergies. Concomitant medications included cetirizine hydrochloride (ZYRTEC) and fluticasone propionate (FLONASE) from unknown dates taken for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 21Mar2021 at 12:00, 2 days after the shot the patient came in from outside and her vision became dark, it had been sunny outside and this was not normal for the patient and few days after that the patient was in shower and vision was funny. On 05Apr2021, 17 days after the shot, the patient was looking at her phone screen in the evening and experienced weird splotches in vision. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the events vision became dark, vision was funny and weird splotches in vision was unknown at the time of this report. No follow-up attempts are needed. No further information is expected.
I started to get a headache around 6:30 - by 9:30 the whole right side of my head felt as if it had a knife going from the base of my skull though my eye out the top of my skull. I was up most of the night with the most severe head pain that I think I've ever experienced. My husband stayed up most of the night with meI had taken 2 Tylenol and a muscle relaxer-Ophedrine?  It did nothing for the pain. -I finally fell asleep around 5am and woke at around 7am.  The head pain was gone. I had another duller headache the next night but not bad. Also had nasal drip and a few chills but that didn't last long.   ( I think I might've had Covid in Feb 2020-I was sick for 4 weeks with strange symptoms that ranged from headaches, extreme nasal drip, dry cough, exhaustion, 3 days of inability to  taste food but no fever)
70 Days after First Shot, No Second Shot; Caller's wife got the first dose 8 weeks ago and wants to now get the second dose.; This spontaneous case was reported by a consumer and describes the occurrence of INTENTIONAL PRODUCT USE ISSUE (Caller's wife got the first dose 8 weeks ago and wants to now get the second dose.) and PRODUCT DOSE OMISSION ISSUE (70 Days after First Shot, No Second Shot) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced INTENTIONAL PRODUCT USE ISSUE (Caller's wife got the first dose 8 weeks ago and wants to now get the second dose.). On 11-Jun-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (70 Days after First Shot, No Second Shot). On 02-Apr-2021, INTENTIONAL PRODUCT USE ISSUE (Caller's wife got the first dose 8 weeks ago and wants to now get the second dose.) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (70 Days after First Shot, No Second Shot) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant drug was not reported. Treatment medication was not reported. It was reported that patient didn't receive second dose due to procrastination.   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Follow up received contact information and information on Adverse event updated
Patient requested bivalent booster and received monovalent dose.  No adverse effects noted upon follow up.
Pt called from home stating that she was having a reaction to vax, complaint of burning, tingling in hands, redness and progressive with symptoms bilaterally. Took Benadryl
While showering on 03/03/05, mother noted child's right deltoid to be red, hard, hot and possibly swollen. Took child to the ER where she was diagnosed with cellulitis and given Keflex 250 mg for 7day, also told to use frequent warm compresses. Child is moving limb without pain or restriction.
Chest Discomfort about a week after 1st does; Sporatic pain every day.  Went to doctor on 4/21/21 as the 2nd dose was scheduled for 4/29/21 and was not sure I should get it.  Performed EKG and Lab work and was sent for a Stress Echo and Arterial Doppler.  Those tests were performed on May 19, 2021.  All results were normal.
This is a spontaneous report from a contactable consumer or other non-hcp (Patient). A 41-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection; Lot Number: EL3147) via an unspecified route of administration (age at vaccination 41-year) on 21Jan2021 as dose 2, single for COVID-19 immunization. Medical history included asthma from an unknown date and unknown if ongoing. Concomitant medications included ibuprofen; paracetamol (TYLENOL); ipratropium bromide, salbutamol sulfate (COMBIVENT); salbutamol (VENTOLINE [SALBUTAMOL]); all taken for an unspecified indication, start and stop date were not reported. Historical vaccine includes first dose of BNT162B2 (Lot Number: EL1284) on 30Dec2020 for COVID-19 immunization. On an unspecified date the patient experienced chest pain. The clinical outcome of the events was unknown.  Follow-up attempts completed. No further information expected.
began limping on rt leg around 6JAN-could not walk w/o falling by 8JAN; taken to ER seen by MD 8JAN no tem; dx ROM & treated 18DEC-OM resolved 8JAN;
I myself a healthy physician with no prior medical illnesses received  Pfizer COVID19 vaccine first on 12/18/20 and second dose on 1/8/21 both doses at Hospital , ( they have the information of the lots)- Then on March 19th I started to develop an acute ascending sensory symptoms first in feet and then arms ; also involved torso . Sensory symptoms consisted of pins and needles and paresthesias . They persists on even today but less intense . Also had temperature dysregulation of the feet when shoes worn. There seem to have also some changes in my sweat gland activity. Saw my PCP and neurologist with working diagnosis of acute sensory neuropathy of unclear etiology. Though this could be idiopathic but  like to check out if any association with  COVID19 vaccine as this only association i could think about in healthy patient ie myself with no medial issues or any acute illness recently nor any systemic disorders to account for symptoms ; wanted to report so that you are aware and I personally wanted to see if this is being recognized in other vaccine recipients  and might help me to arrive at a diagnosis.
seen by MD 8FEB99 arm red, hot & swollen;arms placed in a sling, given Lortab, but not able to tolerate;reported by MD 10FEB99;
A female patient, in her early forties, experienced fever and vomiting after receiving RabAvert. The patient is an animal handler with no medical diagnosis. she received her first dose of RabAvert for pre-exposure prophylaxis on 07/11/2001. On 07/14/2001, the patient complained of fever of 103 degrees and vomiting. The fever was self treated with acetaminophen and the vomiting was untreated. The symptoms resolved after two days.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and genders. The reporter stated that, on an unspecified date, an unknown number of doses of PEDVAXHIB (dose, lot#, expiration dates not provided) that were stored at 48 degrees F for 20 minutes, then exposed to 47 degrees for 9 minutes have been administered. No adverse effects were reported. Follow up information has been received on 22-JUL-2014 from a receptionist. The reporter stated that there were two different lot numbers of PEDVAXHIB that were included in the temperature excursion: Lot # J016188, expiration date: 02-OCT-2016 and lot # J015437, expiration date: 09-OCT-2016. The receptionist did not have any additional information to share with Merck. Follow up information has been received from the registered nurse who provided patients' details. This report refers to a 9-weeks old infant of unknown gender. On 19-JUN-2014, the patient was vaccinated with a dose of PEDVAXHIB lot number J016188, expiration date: 02-OCT-2016, (dose and route were not reported) that was improperly stored. No adverse effects reported. This is one of several reports received from the same reporter. Additional information is not expected because follow up had been obtained.
throwing up; dry heaving; really violent shaking; freezing cold; This spontaneous case was reported by a health care professional and describes the occurrence of VOMITING (throwing up), RETCHING (dry heaving), TREMOR (really violent shaking) and FEELING COLD (freezing cold) in an 87-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     No medical history reported.     On 04-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 2 dosage form. On 04-Mar-2021, the patient experienced VOMITING (throwing up), RETCHING (dry heaving), TREMOR (really violent shaking) and FEELING COLD (freezing cold). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 05-Mar-2021, RETCHING (dry heaving), TREMOR (really violent shaking) and FEELING COLD (freezing cold) outcome was unknown. At the time of the report, VOMITING (throwing up) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 26-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 24Oct2022 as dose 5 (booster), single (Lot number: GJ6665) at the age of 26 years for covid-19 immunisation; BNT162b2 (BNT162B2), on 02Feb2021 as dose 1, single (Lot number: EL9269), on 23Feb2021 as dose 2, single (Lot number: EN6200), on 16Oct2021 as dose 3 (booster), single (Lot number: FF2589) and on 18Mar2022 as dose 4 (booster), single (Lot number: FK9894) for covid-19 immunisation. The patient's relevant medical history included: "Allergies" (unspecified if ongoing); "Asthma" (unspecified if ongoing); "Autism" (unspecified if ongoing); "ADHD" (unspecified if ongoing). Concomitant medication(s) included: ESCITALOPRAM, start date: 01Jan2022; HYDROXYZINE, start date: 01Sep2022; AMPHETAMINE SALTS, start date: 01Sep2022; PRAZOSIN, start date: 01Nov2022; VERAPAMIL, start date: 01Jan2021; TOPIRAMATE, start date: 01Jan2019; ADVAIR, start date: 01Mar2022. Past drug history included: Amoxicillin, reaction(s): "Known allergies". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19; Positive, notes: Still being positive for covid-19. Therapeutic measures were taken as a result of vaccination failure, covid-19 included Paxlovid treatment from 25Nov2022 to 30Nov2022.
Pt developed benign acral papulovesicular eruption on day 20 after vaccination.
pt. received vaccine @ 1420,  within 5 minutes of sitting in chair, pt. c/o feeling hot and nauseated, had syncopal episode, and small seizure like activity, then arroused with physical stimuli, pt. then vomited large amount,  Pt. was taken to gurney,  Team alert called and pt. taken to ED for evaluation 129/92, 100%, 92 heart rate
Approximately 1 week after my vaccination (Dose 1) I experienced the following symptoms: Left ear dermatitis. I assume it was an ear infection and consulted with an ENT and was diagnosed with Tinnitus. Up to this day (04/28/2022) I still have it and have not recovered.
After obtaining the vaccination, the patient went to stand up and indicated she did not feel right. Patient lost consciousness and would have fallen to the floor but pharmacy technician was able to catch her and lower her gently to the floor. Patient was unconscious for a few  moments before coming back around. Patient vomited upon coming alert and indicated she was very hot. Cold compresses were placed on patients face and neck. Ambulance was called and transported the patient to the hospital. Per patient, the hospital indicated she had vasovagal syncope. Patient was treated with IV fluids and released the same day.
4 PM chills and muscle shakes 6 PM sweating fever loss of appetite 7:30 PM body temp 102 degrees Treated with aspirin and several glasses cold tap water. Fever subsided by 11 PM
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 68-year-old female patient who received SHINGRIX (batch number B9739, expiry date unknown) for prophylaxis. Previously administered products included Zostavax vaccine (age 60 received the Zostavax vaccine). On 31st May 2018, the patient received SHINGRIX (intramuscular). On 31st May 2018, less than a day after receiving SHINGRIX, the patient experienced injection site pain and injected limb mobility decreased. On an unknown date, the patient experienced muscle pain. On an unknown date, the outcome of the injection site pain was not recovered/not resolved and the outcome of the injected limb mobility decreased and muscle pain were unknown.  It was unknown if the reporter considered the injection site pain, injected limb mobility decreased and muscle pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient reported that she received the SHINGRIX vaccine on left arm at 3:00 PM. She experienced soreness at the injection site. She claims that she could not comfortably put her arm all the way up without bending and her arm still hurts as it did the first day she received the vaccination. The reporter called because they had a reaction to a, the new shingles shot. They understood that there would be some muscle pain, but it had been a matter of months, and she just wanted to find out if there was anything, any kind of a precedent set. The reporter did an inquiry and she thought the whole issue was proceeding as normal, since there wasn't any side effect issue that could be resolved over the phone. This case has been linked with US2018147956, reported by same reporter.
sick @ stomach;vomiting & diarrhea;weak-couldn't stand had to crawl to bathroom & then to bed;
Chicken pox started on face and belly. Spread to whole body. Doctor said she has chicken pox from getting the vaccine.
After receiving the vaccine my left arm was sore. I had stiffness in my neck. I started getting headaches, and during the evening I had chronic dry heaving. When I vomited there was just bile and no food. I had high fevers, and everything hurt from head to toe. I don't know if it was a normal reaction or if it trigged my autoimmune disease. I was so weak for 3 days my husband had to help me out of bed. On the 4th day, I started to feel better. I was just dragging but I could get out of bed on my own.  On the 5th day I felt okay. I kept taking Tylenol for fever throughout those days. I was also drinking water with electrolytes and eating Pedialyte ice pops. If I ate anything else I would start throwing up again. My husband also rubbed some type of alcohol all over my body to try to help with symptoms.
sensitivity to light; headache; nausea; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Mar-2021 and was forwarded to Moderna on 09-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PHOTOPHOBIA (sensitivity to light), HEADACHE (headache) and NAUSEA (nausea) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029A21A and un) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2021, the patient experienced PHOTOPHOBIA (sensitivity to light), HEADACHE (headache) and NAUSEA (nausea). On 08-Mar-2021, PHOTOPHOBIA (sensitivity to light), HEADACHE (headache) and NAUSEA (nausea) had resolved.            No relevant concomitant medications reported.  No treatment information was provided.
she had a stroke after her last Pfizer booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete; unknown manufacturer), for COVID-19 immunization. The following information was reported: CEREBROVASCULAR ACCIDENT (medically significant), outcome "unknown", described as "she had a stroke after her last Pfizer booster".  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.